|
"yen fs"的相關文件
顯示項目 21-30 / 90 (共9頁)
<< < 1 2 3 4 5 6 7 8 9 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2024-06-12 |
Sodium-glucose cotransporter-2 inhibitors and nephritis among patients with systemic lupus erythematosus
|
Yen, FS;Wang, SI;Hsu, CC;Hwu, CM;Wei, JCC |
| 國家衛生研究院 |
2024-04-30 |
Sodium-glucose cotransporter-2 inhibitors and the risk for dialysis and cardiovascular disease in patients with stage 5 chronic kidney disease
|
Yen, FS;Hwu, CM;Liu, JS;Wu, YL;Chong, K;Hsu, CC |
| 國家衛生研究院 |
2024-04 |
Metformin and the risks of cellulitis, foot infections, and amputation in patients with type 2 diabetes
|
Yeh, YK;Yen, FS;Wei, JC;Hu, KC;Yu, TS;Hsu, CC;Hwu, CM |
| 國家衛生研究院 |
2024-01-04 |
Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes
|
Yen, FS;Hou, MC;Wei, JCC;Shih, YH;Hwu, CM;Hsu, CC |
| 國家衛生研究院 |
2023-12-20 |
Sodium-glucose cotransporter 2 inhibitors and risk of retinopathy in patients with type 2 diabetes
|
Yen, FS;Wei, JCC;Yu, TS;Hung, YT;Hsu, CC;Hwu, CM |
| 國家衛生研究院 |
2023-11-30 |
Parental income level and risk of developing type 2 diabetes in youth
|
Yen, FS;Wei, JCC;Liu, JS;Hwu, CM;Hsu, CC |
| 國家衛生研究院 |
2023-10-31 |
Reply
|
Yen, FS;Hwu, CM;Hsu, CC |
| 國家衛生研究院 |
2023-09-21 |
Reply to the Letter to the Editor: "Glucagon-like Peptide-1 Receptor Agonists: Best Choice for Patients with Cirrhosis and Diabetes?"
|
Yen, FS;Yu, TS;Hsu, CC;Hwu, CM |
| 國家衛生研究院 |
2023-06-16 |
Glucagon-like peptide-1 receptor agonist use in patients with liver cirrhosis and type 2 diabetes
|
Yen, FS;Hou, MC;Cheng-Chung Wei, J;Shih, YH;Hsu, CY;Hsu, CC;Hwu, CM |
| 國家衛生研究院 |
2023-05-09 |
Impact of individual microvascular disease on the risks of macrovascular complications in type 2 diabetes: a nationwide population-based cohort study
|
Yen, FS;Wei, JCC;Shih, YH;Hsu, CC;Hwu, CM |
顯示項目 21-30 / 90 (共9頁)
<< < 1 2 3 4 5 6 7 8 9 > >>
每頁顯示[10|25|50]項目
|
